# Retifanlimab and Ruxolitinib In Solid Malignancies

Source: https://onco.cc/trials/nct07219576/  
OnCo record `nct07219576` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ruxolitinib and retifanlimab in lung cancer, run by University of California, San Diego, now recruiting.

## Summary

Retifanlimab and Ruxolitinib In Solid Malignancies is a phase 1/2, interventional study registered as NCT07219576 by University of California, San Diego, with a registry enrolment figure of 40 participants, started 2026-01-08 and due to reach its primary completion in 2027-12. Interventions recorded: Ruxolitinib; Retifanlimab. Conditions listed: Non Small Cell Lung Carcinoma; Renal Cell Carcinoma. Primary outcome: Recommended phase 2 dose. Lung eligibility wording from the registry: "Advanced or metastatic clear cell renal cell carcinoma or non-small cell lung carcinoma having progressed on prior PD-1/PD-L1 therapy (radiographic progression within 6 months of discontinuing immunotherapy; immunotherapy does not need to be the immediate line of preceding therapy)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: PRISM
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07219576
- Phase: 1/2
- Setting: PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition
- Sponsor: University of California, San Diego
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07219576: https://clinicaltrials.gov/study/NCT07219576

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Retifanlimab](https://onco.cc/drugs/retifanlimab/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- companies: [Incyte](https://onco.cc/companies/incyte/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07219576.json